Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 4 |
| List of Tables | 9 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Epigenetics R&D Pipeline Overview of Epigenetics | 11 | 2 |
| Epigenetics R&D Pipeline Applications of Epigenetics | 13 | 3 |
| Epigenetics in Cancer | 14 | 1 |
| Epigenetics in Other Disease Conditions | 14 | 1 |
| Central Nervous System Disorders | 14 | 1 |
| Epigenetics in Aging | 15 | 1 |
| Diabetes and Obesity | 15 | 1 |
| Epigenetics R&D Pipeline Mechanisms and Targets | 16 | 4 |
| DNA Methyltransferase | 16 | 1 |
| Histone Modifications | 17 | 1 |
| Histone Deacetylase | 17 | 1 |
| Histone Methyltransferase | 17 | 1 |
| New Targets | 18 | 1 |
| Lysine-specific Demethylase 1 | 18 | 1 |
| Enhancer of Zeste Homolog 2 | 18 | 1 |
| Bromodomain and Extra-terminal Proteins | 18 | 1 |
| Ribonucleic Acid | 19 | 1 |
| Non-coding RNA | 19 | 1 |
| Messenger RNA | 19 | 1 |
| Epigenetics R&D Pipeline Marketed Products | 20 | 9 |
| Vidaza (azacitidine) Celgene Corporation | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D | 22 | 1 |
| Adverse Effects | 22 | 1 |
| Zolinza (vorinostat) Merck &Co.Inc. | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D | 24 | 1 |
| Adverse Effects | 24 | 1 |
| Istodax (romidepsin) Celgene Corporation | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D | 26 | 1 |
| Adverse Effects | 26 | 1 |
| Dacogen (decitabine) Eisai Co., Ltd. | 26 | 1 |
| Product Description | 26 | 2 |
| Mechanism of Action | 28 | 1 |
| R&D | 28 | 1 |
| Adverse Effects | 28 | 1 |
| Epigenetic R&D Pipeline Analysis | 29 | 17 |
| Epigenetics R&D Pipeline Pipeline by Stage of Development | 30 | 1 |
| Epigenetics R&D Pipeline Discovery | 31 | 1 |
| Epigenetics R&D Pipeline Phase I | 32 | 5 |
| Epigenetics R&D Pipeline Phase I/II | 37 | 1 |
| Epigenetics R&D Pipeline Phase II | 38 | 3 |
| Epigenetics R&D Pipeline Phase III | 41 | 1 |
| Epigenetics R&D Pipeline Pipeline Analysis by Indication | 42 | 1 |
| Epigenetics R&D Pipeline Pipeline Analysis by Mechanism of Action | 43 | 1 |
| Epigenetics R&D Pipeline Late-stage Pipeline Molecules | 44 | 1 |
| LBH589 (panobinostat) | 44 | 1 |
| Belinostat | 44 | 1 |
| Entinostat | 44 | 1 |
| Vorinostat | 45 | 1 |
| Epigenetics R&D Pipeline Challenges, Opportunities and Trends | 46 | 7 |
| Challenges in Dealing with Epigenetics | 46 | 1 |
| Physician Response to Epigenetic-based Therapies | 47 | 1 |
| Lack of Specificity of Epigenetic-based Therapies | 48 | 1 |
| Toxicity | 48 | 1 |
| Unknown Mechanism of Action | 49 | 1 |
| Better Combination or Better Specificity? | 49 | 1 |
| Technological Challenges | 50 | 1 |
| Opportunities in Epigenetics | 50 | 1 |
| Cancer Market Potential | 50 | 1 |
| New Indications | 51 | 1 |
| Resolving Toxicity and Specificity Issue will Increase Uptake of Epigenetic-based Drugs | 51 | 1 |
| Exploring New Target and Undefined Epigenetic Enzymes | 51 | 1 |
| Trends in Epigenetics Research | 51 | 1 |
| Shift to the New Potential Targets | 51 | 1 |
| Combination Therapies with Two or More Epigenetics Drugs with Different Mechanisms of Action | 51 | 2 |
| Epigenetics R&D Pipeline Leading Players | 53 | 8 |
| Merck &Co., Inc. | 54 | 1 |
| Business Overview | 54 | 1 |
| Epigenetic Portfolio | 54 | 1 |
| Zolinza (vorinostat) | 54 | 1 |
| Novartis AG | 55 | 1 |
| Business Overview | 55 | 1 |
| Epigenetic Portfolio | 55 | 1 |
| LBH589 (panobinostat) | 55 | 1 |
| Syndax Pharmaceuticals, Inc. | 55 | 1 |
| Business Overview | 55 | 1 |
| Epigenetic Portfolio | 56 | 1 |
| Entinostat | 56 | 1 |
| 4SC AG | 56 | 1 |
| Business Overview | 56 | 1 |
| Epigenetic Portfolio | 56 | 1 |
| 4SC-201 | 56 | 1 |
| 4SC-202 | 56 | 1 |
| GlaxoSmithKline Plc | 57 | 1 |
| Business Overview | 57 | 1 |
| Deals | 57 | 1 |
| Celgene Corporation | 57 | 1 |
| Business Overview | 57 | 1 |
| Epigenetic Portfolio | 57 | 1 |
| Vidaza | 57 | 1 |
| Istodax | 57 | 1 |
| MethylGene Inc. | 58 | 1 |
| Business Overview | 58 | 1 |
| Epigenetic Portfolio | 58 | 1 |
| Mocetinostat (MGCD0103) | 58 | 1 |
| Pharmacyclics, Inc. | 58 | 1 |
| Business Overview | 58 | 1 |
| Epigenetic Portfolio | 58 | 1 |
| PCI-24781 | 58 | 1 |
| PCI-34051 | 59 | 1 |
| TopoTarget A/S | 59 | 1 |
| Business Overview | 59 | 1 |
| Epigenetic Portfolio | 59 | 1 |
| Belinostat (PXD 101) | 59 | 1 |
| S*BIO Pte Ltd | 59 | 1 |
| Business Overview | 59 | 1 |
| Epigenetic Portfolio | 59 | 1 |
| SB939 | 59 | 1 |
| Curis, Inc. | 60 | 1 |
| Business Overview | 60 | 1 |
| Epigenetic Portfolio | 60 | 1 |
| CUDC-101 | 60 | 1 |
| CUDC-907 | 60 | 1 |
| Epigenetics R&D Pipeline Strategic Consolidation | 61 | 7 |
| M&A Deals | 62 | 1 |
| Celgene Corporation Completes Acquisition of Gloucester Pharmaceuticals | 62 | 1 |
| Celgene Corporation Acquires the Rights to Vidaza through the Acquisition of Pharmion Corporation | 62 | 1 |
| Eisai Co., Ltd Completes Acquisition of MGI Pharma Inc. | 62 | 1 |
| 4SC AG Successfully Completes Transaction of Nycomed Oncology Projects | 62 | 1 |
| Astex Pharmaceuticals Enters into an Asset Transfer Agreement with GlaxoSmithKline | 62 | 1 |
| Licensing Deals | 63 | 1 |
| Celleron Therapeutics Enters into Licensing Agreement with AstraZeneca Plc | 63 | 1 |
| Spectrum Pharmaceuticals Enters into Licensing Agreement with TopoTarget A/S | 63 | 1 |
| CellCentric Enters into Licensing Agreement with Takeda Pharma | 63 | 1 |
| Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Diseases | 64 | 1 |
| 4SC Enters into Licensing Agreement with Yakult Honsha for Japan for Resminostat | 64 | 1 |
| Co-development Deals | 64 | 1 |
| Pharmacyclics Enters into Collaboration with Les Laboratoires Servier | 64 | 1 |
| Curis Enters into Co-development Agreement with the Leukemia &Lymphoma Society | 65 | 1 |
| Constellation Pharma Enters into Epigenetics Drug Discovery Collaboration Agreement | 65 | 1 |
| Leukemia &Lymphoma Society Enters into an Agreement with EpiZyme Inc. | 65 | 1 |
| Aphios Enters into Research and Co-development Agreement with VivaCell Biotech | 66 | 1 |
| EpiZyme Enters into an Agreement with Eisai | 66 | 1 |
| EpiZyme Enters into Co-development Agreement with GlaxoSmithKline | 66 | 1 |
| EpiTherapeutics Enters into Co-development Agreement with Abbott Laboratories, Inc | 66 | 1 |
| Expectations of Epigenetics Research in the Future | 67 | 1 |
| Epigenetics R&D Pipeline Appendix | 68 | 8 |
| Market Definitions | 68 | 1 |
| Abbreviations | 68 | 2 |
| Sources | 70 | 1 |
| Research Methodology | 71 | 5 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Therapeutic Landscape | 72 | 1 |
| Epidemiology-based Forecasting | 72 | 1 |
| Analogous Forecasting Methodology | 73 | 1 |
| Diseased Population | 73 | 1 |
| Treatment Seeking Population | 73 | 1 |
| Diagnosis Population | 73 | 1 |
| Prescription Population | 73 | 1 |
| Market Size by Geography | 73 | 2 |
| Geographical Landscape | 75 | 1 |
| Pipeline Analysis | 75 | 1 |
| Competitive Landscape | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 75 | 1 |